FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2964426877> ?p ?o ?g. }

• W2964426877 endingPage "5393" @default.
• W2964426877 startingPage "5393" @default.
• W2964426877 abstract "Abstract Objective: To explore the clinical efficacy and adverse reactions of gemcitabine combined with cyclophosphamide, vinblastine and prednisolone (GCVP regiments) in the treatment of relapse and/or refractory non-hodgkin's lymphoma (NHL) in adults patients. Methods: 27 relapse and/or refractory non-hodgkin's lymphoma adult patients (Median:58 years old; range:47-72 years old) were diagnosed and previously treated with regimens such as R-CHOP(E), CHOP(E), MAED (Mitoxantrone, Cytarabine, Etoposide, Dexamethasone), FCM (Fludarabine, Cyclophosphamide, Mitoxantrone) based chemotherapy. There were 19 cases of diffuse large B cell lymphoma, 6 cases of follicular lymphoma, 1 case of NK/T cell type and 1 case of T cell NHL respectively. The GCVP chemotherapy (1000mg/m2 of gemcitabine, 750mg/m2 of cyclophosphamide, 25mg/m2 of vinblastine, intravenous drip on day 1 and day 8, prednisolone 50mg by intravenous drip on day 1 to day 5) were applied to these patients, safety and efficacy analyses were evaluated after two cycles. All patients provided written informed consent. Results: Among all the 27 patients who received GCVP chemotherapy, 3 patients achieved complete remission (CR) (11.11%), 15 patients achieved partial remission (PR) (55.56%), 9 patients with stable disease (SD) (33.33%), the overall response rate (ORR, CR+PR) was 66.67%. Patient's follow-up was continued after treatment, and the median duration of progression-free survival was 60 days. The main adverse events were bone marrow suppression, others were mild to moderate gastrointestinal reactions, a few had mild liver function damage, and it was reversible through hepatoprotection therapy. The most common grade ≥3 adverse events were leukopenia (33.33%, 9/27 cases), thrombocytopenia (40.74%, 11/27 cases), while anemia and gastrointestinal reaction were 11.11% (3/27 cases) and 3.70% (1/27 cases) respectively, no treatment-related death occurred. Discussion and conclusion: The overall outcomes for patients with lymphoma was improved, but there still part of NHL patients suffered form relapse or primary drug resistance, and the prognosis of these patients was poor. Gemcitabine combined with cyclophosphamide, vinblastine and hydrogenated prednisone has a good short-term efficacy in the treatment of relapse and/or refractory NHL. The main adverse reactions were hematologic toxicity and gastrointestinal reaction, mild liver function damage, and no treatment-related death was observed. Disclosures No relevant conflicts of interest to declare." @default.
• W2964426877 created "2019-08-13" @default.
• W2964426877 creator A5001858255 @default.
• W2964426877 creator A5005835095 @default.
• W2964426877 creator A5009683521 @default.
• W2964426877 creator A5016890292 @default.
• W2964426877 creator A5018244700 @default.
• W2964426877 creator A5022176584 @default.
• W2964426877 creator A5022438900 @default.
• W2964426877 creator A5023386987 @default.
• W2964426877 creator A5025782128 @default.
• W2964426877 creator A5026828904 @default.
• W2964426877 creator A5039190327 @default.
• W2964426877 creator A5045353768 @default.
• W2964426877 creator A5060506542 @default.
• W2964426877 creator A5064862848 @default.
• W2964426877 creator A5072548035 @default.
• W2964426877 creator A5077900638 @default.
• W2964426877 creator A5085352453 @default.
• W2964426877 creator A5089363242 @default.
• W2964426877 date "2018-11-29" @default.
• W2964426877 modified "2023-10-01" @default.
• W2964426877 title "Efficacy and Adverse Reactions of Gemcitabine Combined with Cyclophosphamide, Vinblastine and Prednisone Hydrogenation Regiments in Relapse and/or Refractory Non-Hodgkin's Lymphoma" @default.
• W2964426877 doi "https://doi.org/10.1182/blood-2018-99-116600" @default.
• W2964426877 hasPublicationYear "2018" @default.
• W2964426877 type Work @default.
• W2964426877 sameAs 2964426877 @default.
• W2964426877 citedByCount "0" @default.
• W2964426877 crossrefType "journal-article" @default.
• W2964426877 hasAuthorship W2964426877A5001858255 @default.
• W2964426877 hasAuthorship W2964426877A5005835095 @default.
• W2964426877 hasAuthorship W2964426877A5009683521 @default.
• W2964426877 hasAuthorship W2964426877A5016890292 @default.
• W2964426877 hasAuthorship W2964426877A5018244700 @default.
• W2964426877 hasAuthorship W2964426877A5022176584 @default.
• W2964426877 hasAuthorship W2964426877A5022438900 @default.
• W2964426877 hasAuthorship W2964426877A5023386987 @default.
• W2964426877 hasAuthorship W2964426877A5025782128 @default.
• W2964426877 hasAuthorship W2964426877A5026828904 @default.
• W2964426877 hasAuthorship W2964426877A5039190327 @default.
• W2964426877 hasAuthorship W2964426877A5045353768 @default.
• W2964426877 hasAuthorship W2964426877A5060506542 @default.
• W2964426877 hasAuthorship W2964426877A5064862848 @default.
• W2964426877 hasAuthorship W2964426877A5072548035 @default.
• W2964426877 hasAuthorship W2964426877A5077900638 @default.
• W2964426877 hasAuthorship W2964426877A5085352453 @default.
• W2964426877 hasAuthorship W2964426877A5089363242 @default.
• W2964426877 hasBestOaLocation W29644268771 @default.
• W2964426877 hasConcept C126322002 @default.
• W2964426877 hasConcept C141071460 @default.
• W2964426877 hasConcept C2776694085 @default.
• W2964426877 hasConcept C2776715498 @default.
• W2964426877 hasConcept C2776755627 @default.
• W2964426877 hasConcept C2777132456 @default.
• W2964426877 hasConcept C2779263901 @default.
• W2964426877 hasConcept C2780258809 @default.
• W2964426877 hasConcept C2780923524 @default.
• W2964426877 hasConcept C71924100 @default.
• W2964426877 hasConcept C90924648 @default.
• W2964426877 hasConceptScore W2964426877C126322002 @default.
• W2964426877 hasConceptScore W2964426877C141071460 @default.
• W2964426877 hasConceptScore W2964426877C2776694085 @default.
• W2964426877 hasConceptScore W2964426877C2776715498 @default.
• W2964426877 hasConceptScore W2964426877C2776755627 @default.
• W2964426877 hasConceptScore W2964426877C2777132456 @default.
• W2964426877 hasConceptScore W2964426877C2779263901 @default.
• W2964426877 hasConceptScore W2964426877C2780258809 @default.
• W2964426877 hasConceptScore W2964426877C2780923524 @default.
• W2964426877 hasConceptScore W2964426877C71924100 @default.
• W2964426877 hasConceptScore W2964426877C90924648 @default.
• W2964426877 hasIssue "Supplement 1" @default.
• W2964426877 hasLocation W29644268771 @default.
• W2964426877 hasOpenAccess W2964426877 @default.
• W2964426877 hasPrimaryLocation W29644268771 @default.
• W2964426877 hasRelatedWork W1966213558 @default.
• W2964426877 hasRelatedWork W1996596930 @default.
• W2964426877 hasRelatedWork W1998359028 @default.
• W2964426877 hasRelatedWork W2129285584 @default.
• W2964426877 hasRelatedWork W2164965267 @default.
• W2964426877 hasRelatedWork W2270021589 @default.
• W2964426877 hasRelatedWork W2462005191 @default.
• W2964426877 hasRelatedWork W2955625498 @default.
• W2964426877 hasRelatedWork W2964426877 @default.
• W2964426877 hasRelatedWork W2576487797 @default.
• W2964426877 hasVolume "132" @default.
• W2964426877 isParatext "false" @default.
• W2964426877 isRetracted "false" @default.
• W2964426877 magId "2964426877" @default.
• W2964426877 workType "article" @default.